CN103901147B - 一种穿心莲内酯滴丸溶出度的测定方法 - Google Patents
一种穿心莲内酯滴丸溶出度的测定方法 Download PDFInfo
- Publication number
- CN103901147B CN103901147B CN201210587491.5A CN201210587491A CN103901147B CN 103901147 B CN103901147 B CN 103901147B CN 201210587491 A CN201210587491 A CN 201210587491A CN 103901147 B CN103901147 B CN 103901147B
- Authority
- CN
- China
- Prior art keywords
- andrographolide
- dissolution
- reference substance
- solution
- dripping pills
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- BOJKULTULYSRAS-OTESTREVSA-N Andrographolide Chemical compound C([C@H]1[C@]2(C)CC[C@@H](O)[C@]([C@H]2CCC1=C)(CO)C)\C=C1/[C@H](O)COC1=O BOJKULTULYSRAS-OTESTREVSA-N 0.000 title claims abstract description 78
- ASLUCFFROXVMFL-UHFFFAOYSA-N andrographolide Natural products CC1(CO)C(O)CCC2(C)C(CC=C3/C(O)OCC3=O)C(=C)CCC12 ASLUCFFROXVMFL-UHFFFAOYSA-N 0.000 title claims abstract description 78
- 238000004090 dissolution Methods 0.000 title claims abstract description 57
- 239000006187 pill Substances 0.000 title claims abstract description 39
- 238000003556 assay Methods 0.000 title claims description 9
- 239000013558 reference substance Substances 0.000 claims abstract description 47
- 238000012360 testing method Methods 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 25
- 238000002360 preparation method Methods 0.000 claims abstract description 16
- 238000004128 high performance liquid chromatography Methods 0.000 claims abstract description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- 239000012738 dissolution medium Substances 0.000 claims description 23
- 239000002002 slurry Substances 0.000 claims description 10
- RCEAADKTGXTDOA-UHFFFAOYSA-N OS(O)(=O)=O.CCCCCCCCCCCC[Na] Chemical compound OS(O)(=O)=O.CCCCCCCCCCCC[Na] RCEAADKTGXTDOA-UHFFFAOYSA-N 0.000 claims description 8
- 239000000706 filtrate Substances 0.000 claims description 7
- GBMDVOWEEQVZKZ-UHFFFAOYSA-N methanol;hydrate Chemical compound O.OC GBMDVOWEEQVZKZ-UHFFFAOYSA-N 0.000 claims description 7
- 240000002853 Nelumbo nucifera Species 0.000 claims description 3
- 235000006508 Nelumbo nucifera Nutrition 0.000 claims description 3
- 235000006510 Nelumbo pentapetala Nutrition 0.000 claims description 3
- 150000002596 lactones Chemical class 0.000 claims description 2
- 238000004080 punching Methods 0.000 claims 1
- 238000011084 recovery Methods 0.000 abstract description 8
- 239000000243 solution Substances 0.000 description 73
- 239000003814 drug Substances 0.000 description 16
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 13
- 239000002609 medium Substances 0.000 description 11
- 239000000047 product Substances 0.000 description 10
- 239000000203 mixture Substances 0.000 description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 8
- 238000002474 experimental method Methods 0.000 description 8
- 238000005063 solubilization Methods 0.000 description 8
- 230000007928 solubilization Effects 0.000 description 8
- 239000007788 liquid Substances 0.000 description 7
- 239000000463 material Substances 0.000 description 7
- 238000001514 detection method Methods 0.000 description 6
- 239000003643 water by type Substances 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 229940079593 drug Drugs 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- SFNALCNOMXIBKG-UHFFFAOYSA-N ethylene glycol monododecyl ether Chemical compound CCCCCCCCCCCCOCCO SFNALCNOMXIBKG-UHFFFAOYSA-N 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- -1 polyoxyethylene lauryl ether Polymers 0.000 description 3
- 238000005070 sampling Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 101000610640 Homo sapiens U4/U6 small nuclear ribonucleoprotein Prp3 Proteins 0.000 description 2
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 2
- 101001110823 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-A Proteins 0.000 description 2
- 101000712176 Saccharomyces cerevisiae (strain ATCC 204508 / S288c) 60S ribosomal protein L6-B Proteins 0.000 description 2
- 102100040374 U4/U6 small nuclear ribonucleoprotein Prp3 Human genes 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000002924 anti-infective effect Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 206010006451 bronchitis Diseases 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 238000010790 dilution Methods 0.000 description 2
- 239000012895 dilution Substances 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 229920000259 polyoxyethylene lauryl ether Polymers 0.000 description 2
- 238000012216 screening Methods 0.000 description 2
- 238000013112 stability test Methods 0.000 description 2
- 229910021642 ultra pure water Inorganic materials 0.000 description 2
- 239000012498 ultrapure water Substances 0.000 description 2
- YIIRVUDGRKEWBV-UHFFFAOYSA-N (E)-3-(2-((1R,4aS,5R,6R,8aS)-6-hydroxy-5-(hydroxymethyl)-5,8a-dimethyl-2-methylenedecahydronaphthalen-1-yl)ethylidene)furan-2(3H)-one Natural products C=C1CCC2C(C)(CO)C(O)CCC2(C)C1CC=C1C=COC1=O YIIRVUDGRKEWBV-UHFFFAOYSA-N 0.000 description 1
- XMJAJFVLHDIEHF-CRBRZBHVSA-N 14-Deoxy-11,12-didehydroandrographolide Chemical compound C(/[C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@@H](O)[C@]2(CO)C)=C\C1=CCOC1=O XMJAJFVLHDIEHF-CRBRZBHVSA-N 0.000 description 1
- XMJAJFVLHDIEHF-UHFFFAOYSA-N 14-deoxy-11, 12-didehydroandrographolide Natural products OCC1(C)C(O)CCC2(C)C1CCC(=C)C2C=CC1=CCOC1=O XMJAJFVLHDIEHF-UHFFFAOYSA-N 0.000 description 1
- YIIRVUDGRKEWBV-YSDSKTICSA-N 14-deoxy-11,12-didehydroandrographolide Natural products C[C@@]1(CO)[C@H](O)CC[C@@]2(C)[C@H](CC=C/3C=COC3=O)C(=C)CC[C@H]12 YIIRVUDGRKEWBV-YSDSKTICSA-N 0.000 description 1
- YGCYRQKJYWQXHG-RDNQFMDVSA-N 4-[2-[(1r,4as,5r,8as)-5,8a-dimethyl-2-methylidene-5-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]-3,4,4a,6,7,8-hexahydro-1h-naphthalen-1-yl]ethyl]-2h-furan-5-one Chemical compound C([C@@]1(C)[C@H]2CCC(=C)[C@@H](CCC=3C(OCC=3)=O)[C@]2(C)CCC1)O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O YGCYRQKJYWQXHG-RDNQFMDVSA-N 0.000 description 1
- 208000004429 Bacillary Dysentery Diseases 0.000 description 1
- 206010006458 Bronchitis chronic Diseases 0.000 description 1
- 206010012735 Diarrhoea Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 208000004232 Enteritis Diseases 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- 206010017915 Gastroenteritis shigella Diseases 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 206010035737 Pneumonia viral Diseases 0.000 description 1
- 208000018238 Primary Headache disease Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 150000005215 alkyl ethers Chemical class 0.000 description 1
- 208000002399 aphthous stomatitis Diseases 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 238000011088 calibration curve Methods 0.000 description 1
- 208000007451 chronic bronchitis Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 230000007797 corrosion Effects 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 239000009524 danshen dripping Substances 0.000 description 1
- XMJAJFVLHDIEHF-YSDSKTICSA-N dehydroandrographolide Natural products C([C@@H]1C(=C)CC[C@H]2[C@@]1(C)CC[C@@H](O)[C@]2(CO)C)=CC1=CCOC1=O XMJAJFVLHDIEHF-YSDSKTICSA-N 0.000 description 1
- MEEPUSVTMHGIPC-UHFFFAOYSA-N deoxyandrographiside Natural products OC1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O MEEPUSVTMHGIPC-UHFFFAOYSA-N 0.000 description 1
- 150000001983 dialkylethers Chemical class 0.000 description 1
- 238000011978 dissolution method Methods 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- BBGWVUQBIGGVLS-UHFFFAOYSA-N neoandrographolide Natural products CC1(COC2OC(CO)C(O)C(O)C2O)C(O)CCC3(C)C(CCC4=C(O)COC4=O)C(=C)CCC13 BBGWVUQBIGGVLS-UHFFFAOYSA-N 0.000 description 1
- YGCYRQKJYWQXHG-UHFFFAOYSA-N neoandrographoside Natural products C1CCC2(C)C(CCC=3C(OCC=3)=O)C(=C)CCC2C1(C)COC1OC(CO)C(O)C(O)C1O YGCYRQKJYWQXHG-UHFFFAOYSA-N 0.000 description 1
- 229940126701 oral medication Drugs 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 201000005113 shigellosis Diseases 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 206010044008 tonsillitis Diseases 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 208000009421 viral pneumonia Diseases 0.000 description 1
Landscapes
- Investigating Or Analysing Biological Materials (AREA)
Abstract
Description
Claims (4)
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210587491.5A CN103901147B (zh) | 2012-12-28 | 2012-12-28 | 一种穿心莲内酯滴丸溶出度的测定方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201210587491.5A CN103901147B (zh) | 2012-12-28 | 2012-12-28 | 一种穿心莲内酯滴丸溶出度的测定方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN103901147A CN103901147A (zh) | 2014-07-02 |
CN103901147B true CN103901147B (zh) | 2018-04-03 |
Family
ID=50992606
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201210587491.5A Active CN103901147B (zh) | 2012-12-28 | 2012-12-28 | 一种穿心莲内酯滴丸溶出度的测定方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN103901147B (zh) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN106950294A (zh) * | 2017-02-22 | 2017-07-14 | 江西普正植物药科技协同创新有限公司 | 一种穿王消炎胶囊质量检测方法 |
CN107907640A (zh) * | 2017-11-22 | 2018-04-13 | 杭州华东医药集团新药研究院有限公司 | 发酵冬虫夏菌粉片的药效评价方法 |
CN107977546A (zh) * | 2017-11-29 | 2018-05-01 | 广东嘉博制药有限公司 | 一种采用判别法评价药物制剂溶出度相似程度的方法 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552320A (zh) * | 2003-03-05 | 2004-12-08 | 侯文阁 | 穿心莲内酯化合物增溶制备方法及药物制剂 |
CN1911212A (zh) * | 2006-08-24 | 2007-02-14 | 南昌弘益科技有限公司 | 穿心莲内酯滴丸生产方法 |
CN1912614A (zh) * | 2006-08-26 | 2007-02-14 | 南昌弘益科技有限公司 | 穿心莲内酯口服固体制剂质量控制方法 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR100565608B1 (ko) * | 2003-08-30 | 2006-03-29 | 엘지전자 주식회사 | 냉장고 자동제빙기의 결합 구조체 |
US8563728B2 (en) * | 2009-07-09 | 2013-10-22 | Aurobindo Pharma Ltd. | Process for the preparation of Dutasteride |
-
2012
- 2012-12-28 CN CN201210587491.5A patent/CN103901147B/zh active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN1552320A (zh) * | 2003-03-05 | 2004-12-08 | 侯文阁 | 穿心莲内酯化合物增溶制备方法及药物制剂 |
CN1911212A (zh) * | 2006-08-24 | 2007-02-14 | 南昌弘益科技有限公司 | 穿心莲内酯滴丸生产方法 |
CN1912614A (zh) * | 2006-08-26 | 2007-02-14 | 南昌弘益科技有限公司 | 穿心莲内酯口服固体制剂质量控制方法 |
Non-Patent Citations (7)
Title |
---|
Solid–liquid extraction of andrographolide from plants—experimental study, kinetic reaction and model;R.Wongkittipong 等;《Separation and Purification Technology》;20041201;第40卷(第2期);147-154 * |
Solubility of Andrographolide in Various Solvents from (288.2 to 323.2) K;Chen Meili 等;《J. Chem. Eng》;20100604;第55卷(第11期);5297–5298 * |
中药溶出度的研究进展;蒋晔 等;《中成药》;20060331;第28卷(第3期);415-419 * |
穿心莲内酯原料药及其栓剂的研究;赵朝伟;《中国优秀硕士学位论文全文数据库 工程科技Ⅰ辑》;20040901(第3期);B016-231 * |
穿心莲内酯和脱水穿心莲内酯在滴丸中的溶出度相关性检验;樊敏伟 等;《中成药》;20090630;第31卷(第6期);921-923 * |
穿心莲内酯固体分散体的制备及体外溶出度测定;索绪斌 等;《中成药》;20070430;第29卷(第4期);594-596 * |
穿心莲滴丸中穿心莲内酯的体外溶出度研究;宋英 等;《中国实验方剂学杂志》;20081031;第14卷(第10期);11-13 * |
Also Published As
Publication number | Publication date |
---|---|
CN103901147A (zh) | 2014-07-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN105388225B (zh) | 一种含胞磷胆碱钠的药物制剂中udpc的分析检测方法 | |
CN103323550A (zh) | 一种同时检测水中五种药物的方法 | |
CN103901147B (zh) | 一种穿心莲内酯滴丸溶出度的测定方法 | |
CN103454369A (zh) | 一种高效液相色谱检测血液中丙戊酸钠含量的方法 | |
CN108072712B (zh) | 一种sd大鼠血浆中新化合物wsj-557的血药浓度定量分析方法 | |
CN111398475A (zh) | 一种用高效液相色谱法分析硫酸羟氯喹制剂组成的方法 | |
CN110045037A (zh) | 一种检测干血斑中尼洛替尼药物浓度的试剂盒及检测方法 | |
CN101692038B (zh) | 一种脂质体中磷脂含量的测定方法 | |
CN109613128A (zh) | 一种法莫替丁胶囊中主药含量的测定方法 | |
CN105974016B (zh) | 一种同时检测血浆中福沙匹坦和阿瑞匹坦的方法 | |
CN105987961A (zh) | 一种母乳中左乙拉西坦的检测方法 | |
CN105044241A (zh) | 蛇胆川贝液的标准特征图谱的构建及其质量检测方法 | |
CN102809625B (zh) | 一种穿心莲内酯有关物质的测定方法 | |
CN102175823A (zh) | 一种用于中药体外溶出分析的评价方法 | |
CN104914194B (zh) | 一种用气相色谱仪检测薄荷素油滴丸中薄荷脑含量的方法 | |
CN110441421A (zh) | 一种高效液相色谱法测定恩他卡朋片溶出度的方法 | |
CN103543222A (zh) | 一种热毒宁注射液中糖类成分含量的检测方法 | |
CN104833756B (zh) | 一种附甘药物单酯型生物碱的含量测定方法 | |
CN102608231A (zh) | Hplc法测定维生素c泡腾片中维生素c含量的方法 | |
CN111579684B (zh) | 一种胶囊剂的囊材中辣椒总碱的含量测定方法 | |
CN104965031B (zh) | 复方酮洛芬奥美拉唑缓释胶囊的含量测定方法 | |
CN106932347A (zh) | 一种美洛西林酸及其质量指标检测方法 | |
CN107449844B (zh) | 一种测定二巯丁二酸制剂溶出度的方法 | |
CN105806985B (zh) | 一种马钱子苷元生物样品的测定方法 | |
CN112113809B (zh) | 一种超声乳化-悬浮溶剂固化微萃取uv测定抗艾药含量的方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
C06 | Publication | ||
PB01 | Publication | ||
EXSB | Decision made by sipo to initiate substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB02 | Change of applicant information |
Address after: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Applicant after: TASLY PHARMACEUTICAL GROUP Co.,Ltd. Address before: 300410 Tianjin city Beichen District Huaihe road and road intersection Dingjiang tianzhijiao Park forensic Center for Intellectual Property Department Applicant before: TASLY PHARMACEUTICAL GROUP Co.,Ltd. |
|
CB02 | Change of applicant information | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
CB03 | Change of inventor or designer information |
Inventor after: Liu Peng Inventor after: Bian Ning Inventor after: Ge Dandan Inventor after: Hou Chunlian Inventor after: Sun Yuxia Inventor after: Cao Fenglan Inventor before: Bian Ning Inventor before: Ge Dandan Inventor before: Hou Chunlian Inventor before: Sun Yuxia Inventor before: Cao Fenglan |
|
CB03 | Change of inventor or designer information |